Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
The science of slowed gastrointestinal motility GLP-1 receptor agonists act on the gutbrain axis and are known to slow gastric emptying and overall gastrointestinal transit , contributing to early satiety and appetite suppression. As intestinal transit slows, the colon has more time to absorb water from stool , leading to hard, dry stools that are difficult to pass . Constipation is a common, dose-related adverse effect listed in FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) and is most frequently reported during dose escalation , with improvement over time., Step-by-Step MD Protocol for Relief 1
Tirzepatide operates on a dual mechanism by activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
This product is not intended to affect the structure or function of the body and is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man
Wegovy contains Semaglutide and is approved for chronic weight management in eligible adults who meet BMI criteria
The math does not change based on body weight, only the target dose changes
US$ 23.39
US$ 24.30
US$ 23.95
US$ 26.24
